HepQuant Announces Approval of Third Investigational Device Exemption Application

HepQuant SHUNT™ Liver Diagnostic Kit for use in a clinical study in subjects with NASH F4

DENVER, CO (March 21, 2017) -- HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that its first application for an Investigational Device Exemption ("IDE") for its HepQuant SHUNT™ Liver Diagnostic Kit has been approved by the Food and Drug Administration ("FDA") for use in a clinical study in subjects with Non-Alcoholic Steatohepatitis ("NASH") and a biopsy histology score of F4.

Founder and Chief Executive Officer of HepQuant, LLC, Dr. Gregory T. Everson said the milestone represents HepQuant's further development of the SHUNT test in subjects with more advanced NASH. "Assessment tools such as HepQuant SHUNT may be important to determine whether a subject has disease severity that is advancing, regressing or remaining unchanged."

About HepQuant

HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.

MEDIA CONTACT
Tom Kennedy, Corporate Communications
Ph: (303) 548-3056 | E: tom.kennedy@hepquant.com